Seborrhea, more precisely called seborrheic dermatitis, is a chronic inflammatory skin condition that produces scaly, greasy patches on areas of the body rich in oil glands. It affects roughly 4.4% of people worldwide, making it one of the most common skin conditions. Despite how often it appears, several facts about seborrhea surprise people: it’s driven by a yeast that lives on everyone’s skin, it’s closely linked to certain neurological conditions, and it cannot be cured, only managed through ongoing treatment.
Where It Appears on the Body
Seborrheic dermatitis targets skin with the highest concentration of oil-producing glands. In adults and teenagers, that means flaky, greasy, reddish patches on the scalp, the creases beside the nose, the eyebrows, behind the ears, the center of the chest, and the upper back. The armpits and groin can also be involved. These aren’t random locations. Oil glands in these zones create the exact environment the condition needs to thrive.
In infants, the same process produces what most parents know as cradle cap: thick, yellowish, crusty scales on the top of the head. It typically appears between 3 weeks and 12 months of age, peaking around 3 months when roughly 70% of infants show some degree of it. By age one to two, only about 7% of children are still affected. In most babies, it resolves on its own without treatment.
A Yeast on Your Skin Drives It
Everyone carries a yeast called Malassezia on their skin. It’s part of the normal skin ecosystem. But in people with seborrheic dermatitis, the relationship between this yeast and the skin’s immune system goes wrong. Malassezia feeds on the oils your skin produces, breaking them down with enzymes called lipases. That process releases free fatty acids and other byproducts that irritate the skin and compromise its protective barrier.
Strains of Malassezia taken from seborrheic dermatitis patches produce significantly more biologically active compounds than strains taken from healthy skin. These compounds trigger a type of immune response that isn’t a true allergic reaction but instead an irritant-driven inflammatory cascade. The body sends immune cells to the area, which causes the redness and swelling that distinguish seborrheic dermatitis from simple dandruff. Dandruff produces flaking without that visible inflammation.
Who Gets It and Why
The condition follows a U-shaped pattern across the lifespan: it’s common in infancy, relatively stable through adulthood, and ticks upward again in older age. The overall burden on quality of life peaks in people 85 and older. Men develop it more often than women, likely because androgens (male hormones) increase oil gland activity.
Certain medical conditions dramatically raise the risk. More than half of people living with Parkinson’s disease develop seborrheic dermatitis. The connection appears related to changes in the nervous system’s regulation of oil production and skin immunity. HIV infection also greatly increases risk, and in people with compromised immune systems, the condition tends to be more severe and widespread.
Environmental triggers matter too. Cold, dry weather is a reliable trigger for flare-ups. Stress, sleep deprivation, and hormonal shifts can also worsen symptoms. Because the underlying yeast and oil production never fully go away, most people cycle between periods of relative calm and active flares throughout their lives.
How It Differs From Psoriasis
Seborrheic dermatitis and scalp psoriasis can look similar enough to confuse even experienced clinicians. A few features help tell them apart. Psoriasis scales tend to be thicker and drier, while seborrheic dermatitis scales are greasy and yellowish. Psoriasis patches often extend beyond the hairline onto the forehead or behind the ears, with well-defined borders. Seborrheic dermatitis usually has less distinct edges and stays closer to oil-rich zones. In some cases, the two conditions overlap in a presentation sometimes called sebopsoriasis.
Treatment Focuses on Controlling the Yeast
Because a yeast drives the inflammation, the first line of treatment targets that yeast directly. For scalp involvement, medicated shampoos containing antifungal ingredients are the standard approach. Ketoconazole at 2% concentration and selenium sulfide at 2.5% are among the most studied options. These shampoos are typically left on the scalp for several minutes before rinsing to give the active ingredient time to work.
For the face, treatment gets more nuanced because facial skin is thinner and more sensitive. Mild antifungal creams work for many people. When inflammation is significant, prescription anti-inflammatory creams that calm the immune response without the side effects of long-term steroid use have shown effectiveness and a favorable safety profile for ongoing use. These are applied two to three times per week as tolerated.
Short courses of mild topical steroids can bring a flare under control quickly, but they aren’t suitable for long-term use, especially on the face, where they can thin the skin over time.
It Comes Back
This is perhaps the most important thing to understand about seborrhea: it’s chronic and relapsing. Current treatments achieve symptom control, not a cure. Relapses are frequent, and many people find that stopping treatment brings symptoms back within weeks. A recent narrative review noted that conventional therapies generally achieve only partial symptom control and are frequently followed by relapses.
That’s why maintenance therapy matters. For the scalp, using a medicated shampoo once a week even during clear periods helps prevent flares from returning. For the trunk, twice-weekly use of an antifungal wash or cream serves the same purpose. The goal shifts from eliminating symptoms to keeping the yeast population and the skin’s inflammatory response low enough that patches don’t reappear.
Most people with seborrheic dermatitis eventually find a routine that keeps it manageable. The condition doesn’t damage organs or spread to others. It isn’t contagious. But it is persistent, and accepting that ongoing maintenance is part of the deal tends to lead to better long-term outcomes than treating it only when it flares.